Premenstrual Dysphoric Disorder in Adults

ICD-10 code: F32.81

Premenstrual dysphoric disorder (PMDD) is part of a cluster of diagnoses called the depressive disorders. Depressive disorders are a group of psychiatric conditions that include:

  • Major depressive disorder
  • Persistent depressive disorder (dysthymia)
  • Premenstrual dysphoric disorder
  • Disruptive mood dysregulation disorder (children only)
Header image

The depressive disorders are characterized primarily by mood disturbance (sad, empty, or irritable mood). Individuals with depressive disorders often experience significant somatic changes, such as disruptions in sleep (insomnia or hypersomnia), eating (overeating or loss of appetite), or energy level. Changes in cognition, such as difficulty concentrating, indecisiveness, and morbid ideation (such as thoughts of death) are also common.

Individuals with major depressive disorder experience pervasive sadness or anhedonia (loss of interest) along with significant changes in somatic and/or cognitive functioning. To be diagnosed, these problems must be present nearly every day for at least two weeks. Individuals with persistent depressive disorder (dysthymia) experience similar symptoms, including sad mood and problems with somatic and/or cognitive functioning that occur most days for at least two years. Individuals with premenstrual dysphoric disorder experience marked changes in mood and interpersonal functioning that begin sometime following ovulation and remit within a few days of the onset of menses. Disruptive mood dysregulation disorder is diagnosed in children under 12 years old who experience persistent irritability and extreme behavioral dyscontrol.

Dashboard mockup

What is premenstrual dysphoric disorder?

PMDD is a psychiatric disorder that will affect approximately 1-8% of menstruating women at some point in their lives. An individual with PMDD experiencesa variety of mood-related symptoms that emerge in the final week before the onset of menses, improve within a few days after the onset of menses, and become minimal or absent in the week post-menses.

Learn More

To be diagnosed with PMDD, a person must experience at least five diagnostic symptoms. These five symptoms must include at least one symptom from the following list:

  • Affective lability,which can include mood swings, feeling suddenly sad or tearful, or being very sensitive to rejection
  • Irritability or anger, or increased interpersonal conflicts
  • Depressed mood, hopelessness, or self-deprecating thoughts,or
  • Anxiety, tension, or restlessness

The five symptoms must also include at least one symptom from the following list:

  • Anhedonia, or decreased interest in one's usual activities
  • Difficulty concentrating
  • Lethargy or fatigue
  • Appetite disturbance, including marked change in appetite, overeating, or specific food cravings
  • Sleep disturbance, including insomnia or hypersomnia
  • Overwhelmed or out of control feelings
  • Physical symptoms, such as breast swelling or tenderness, joint or muscle pain, a sensation of bloating, or weight gain

PMDD should not be diagnosed if the symptoms are solely an exacerbation of another disorder, such as major depressive disorder.

PMDD symptoms may be subject to memory biases. For example, a person may misremember when symptoms occur, attributing them to the menstrual cycle when in fact there is no association. Therefore, PMDD diagnoses should be confirmed through the use of prospective daily symptom ratings for at least two menstrual cycles. Prior to confirmation, the diagnosis should be listed as provisional.

Dashboard mockup

Understanding Premenstrual Dysphoric Disorder

PMDD severity can range from mild to severe. In severe cases, PMDD may lead to impaired ability to fulfill responsibilities at work, school, or home while symptoms are present. PMDD may also cause problems in interpersonal relationships, for example if irritability and rejection sensitivity are pronounced. Many people with PMDD also have other psychiatric conditions, most commonly a history of a major depressive episode.

Learn More

Currently, little is known about the precise biological factors that contribute to PMDD. However, increased sensitivity or other abnormalities in neuroendocrine-modulated neurotransmitters such as serotonin and the hypothalamic-pituitary-gonadal axis have been proposed as candidate mechanisms. Neurobiological abnormalities include abnormal activation in the amygdala, which is involved in emotion generation, and the orbitofrontal cortex, which is involved in emotion regulation. The disorder appears to be heritable, although having a genetic predisposition to PMDD does not necessarily mean that someone will develop PMDD.

Dashboard mockup

How is premenstrual dysphoric disorder treated?

PMDD is treatable. Published treatment guidelines for PMDD include those from theAssociation of Reproductive Health Professionals, the Journal of Women's Health, and the American Academy of Family Physicians.

Currently, clinical research suggests that antidepressant medications, which work by altering the amount of serotonin in the brain, are effective for treating PMDD. Specific medications that have shown efficacy for the treatment of PMDD include:

  • Selective serotonin reuptake inhibitors (SSRIs), including citalopram, escitalopram, fluoxetine, and sertraline. SSRIs are generally considered a first-line pharmacological treatment for PMDD. SSRIs can be administered continuously throughout the month or intermittently, corresponding to the menstrual cycle.
  • Other serotonergic antidepressant medications, including velafaxine and clomipramine

Additionally, the following treatments have shown some promise in treating PMDD:

  • Vitamin supplementation with calcium or vitamin B6
  • Hormone therapies, including the oral contraceptive drosperinone, 3mg/ethinyl estradiol, 20mcg (Yasmin), estrogen, and gonadotropin-releasing hormone agonists such as buserelin and goserelin
  • Herbal supplementation with chasteberry
  • Cognitive-behavioral therapy consists of a variety of interventions designed to help the patient think and behave in more adaptive ways. Some specific components of cognitive-behavioral therapy include behavioral activation, which involves increasing the individual's engagement in potentially rewarding activities, and cognitive therapy, which involves helping the person to challenge inaccurate beliefs that they may hold (such as "I'll never feel better" or "I'm not a worthwhile person").

Additional Treatments to Consider

Preliminary evidence suggests that the following strategies, while not a substitute for the more well-validated treatments described above, might be considered.

  • Aerobic exercise
  • Consuming more high-protein foods or complex carbohydrates, which increase tryptophan, a building block of serotonin